Expert Interviews

Matthew Budoff, MD: Clinical Usefulness of CAC Scores

September 11, 2020

An interview examining the use of coronary artery calcium scores for predicting CV events and stroke risk in real-world settings.

Diana Isaacs, PharmD: An Overview of Insulin Affordability in 2020

September 01, 2020

A look at the state of insulin affordability in 2020 and how the ongoing pandemic has impacted the situation.

Managing Hyperglycemia in COVID-19

August 17, 2020

A professor from Michigan Medicine discusses recent research from the institute and how protocols implemented at Michigan Medicine to manage the increased risk of severe outcomes associated with hyperglycemia in COVID-19.

Daniel Spratt, MD: Estrogen, Birth Control, and COVID-19 Clotting Risk

August 04, 2020

A practicing endocrinologist and professor of medicine offers insight into the potential for increase in risk of blood clots in certain groups of women if they were to contract COVID-19.

Video: When Should Metformin be Omitted?

November 10, 2017

Guidelines say metformin should be stopped where there is acute kidney injury or risk of renal compromise. Now there is evidence to support those recommendations.

Diabetes Self-Management: Nurse-Led Approach

May 17, 2017

Patients were randomized to standard care, nurse-led education intervention, or nurse-led education plus acceptance therapy.

Renal Effects: SGLT2 Inhibitors in Type 2 Diabetes

April 21, 2017

A meta-analysis compared the renal side effects of SGLT2 inhibitors in patients with type 2 diabetes.

CV Events: Safety of Insulin

April 14, 2017

A study compared mortality and major adverse cardiovascular events in patients with type 2 diabetes prescribed metformin or insulin.

Can Liraglutide Delay Diabetes Onset?

March 31, 2017

Researchers compared time to onset of diabetes in a group of patients with obesity and pre-diabetes treated with liraglutide or placebo.

Dapagliflozin: All-Cause & Cardiovascular Mortality

March 20, 2017

Research has shown the beneficial effects of empagliflozin on all-cause and CV mortality. Does the same hold true for another SGLT2 inhibitor?